Inclusion Criteria:

- Histologically confirmed stage III or IV ovarian epithelial, fallopian tube, or
primary peritoneal cancer that was treated with only 1 prior first-line chemotherapy
regimen (platinum/taxane-based)

- Clinically and radiologically without evidence of measurable and nonmeasurable
disease

- Symptomatic ascites and pleural effusions are considered nonmeasurable disease

- Must have a biochemical recurrence

- CA 125 must have been normal prior to or normalized during first-line therapy
and then subsequently rose to exceed twice the upper limit of normal

- Patients entering study with a CA 125 level less than 100 U/mL must be confirmed
a second time within a period of not more than 4 weeks

- Patients with a CA 125 level of at least 100 U/mL may be entered without
confirmatory measurement

- Ineligible for a higher priority Gynecologic Oncology Group protocol (if one exists)

- No history of brain metastases

- Performance status - GOG 0-1

- Absolute neutrophil count at least 1,500/mm^3

- Platelet count at least 100,000/mm^3

- Bilirubin no greater than 1.5 times upper limit of normal (ULN)

- SGOT no greater than 2.5 times ULN

- Alkaline phosphatase no greater than 2.5 times ULN

- Creatinine no greater than 1.5 times ULN

- Creatinine clearance at least 60 mL/min

- No history of deep venous thrombosis

- No prior cerebrovascular accident

- No history of pulmonary embolism

- No significant infection

- No grade 2 or greater sensory or motor neuropathy

- No other malignancy within the past 5 years except nonmelanoma skin cancer or
carcinoma in situ

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use at least 1 highly active method and at least 1 additional
effective method of contraception for 4 weeks before, during, and for 4 weeks after
study participation

- No prior immunotherapy (e.g., interleukins)

- No prior biological response modifiers (e.g., monoclonal antibodies)

- No prior antiangiogenic agents (e.g., carbonic anhydrase inhibitors)

- At least 3 weeks since prior anticancer chemotherapy and recovered

- No prior or concurrent tamoxifen or other selective estrogen receptor modulators

- At least 4 weeks since prior and no concurrent hormones (e.g., estrogen or
progesterone)

- At least 3 weeks since prior anticancer radiotherapy and recovered

- At least 3 weeks since prior anticancer surgery and recovered

- Prior second-look surgery without cytoreduction allowed

- At least 3 weeks since other prior anticancer therapy and recovered

- No prior interval cytoreduction

- No concurrent full-dose therapeutic anticoagulation

- No concurrent antiseizure medications for seizure disorder

- No concurrent bisphosphonates (e.g., zoledronate)